| Dr Sarah Eilerman Weinel, MD | |
|
215 Thomas More Pkwy Ste A, Crestview Hills, KY 41017-3498 | |
| (859) 341-9588 | |
| (859) 341-0078 |
| Full Name | Dr Sarah Eilerman Weinel |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 21 Years |
| Location | 215 Thomas More Pkwy Ste A, Crestview Hills, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194866715 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 41204 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Elizabeth Edgewood | Edgewood, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dermatology Specialists Of Northern Kentucky Psc | 2163485863 | 2 |
News Archive
Patients with epilepsy often undergo evaluation by concurrent video and EEG monitoring (vEEG) for therapeutic planning, including possible epilepsy surgery. Seizures during monitoring increase the diagnostic yield and requires the withdrawal of anticonvulsant drugs (AEDs) to allow seizures to occur.
Inhibitex, Inc. today announced that the independent data safety monitoring board (DSMB) responsible for reviewing safety data from the Company's ongoing Phase II clinical trial of FV-100 met, as scheduled, after the Company had provided it with complete 30-day follow-up safety data on the third quartile (75%) of the patients that the Company plans to enroll in the trial. Based upon its review, the DSMB recommended that the trial continue to completion without modification.
Align Technology, Inc. today announced the launch of Invisalign® G3, the most significant collection of new features and innovations in the company's history. Invisalign G3 is engineered to deliver even better clinical results, with new aligner and software features that make it easier to use Invisalign with Class II and Class III patients, new SmartForce™ features designed for increased predictability of certain tooth movements, and simpler, more intuitive software to streamline treatment planning and review.
Targeting c-Met may be a promising personalized treatment method for approximately 45 percent of patients with hepatocellular carcinoma (HCC) who have c-Met-positive tumors, according to study results presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
First-trimester screening of pregnant women for asymptomatic bacteriuria - higher than normal bacteria levels without symptoms of a bladder infection - is recommended by the Canadian Task Force on Preventive Health Care in an updated guideline in CMAJ
› Verified 6 days ago
| Entity Name | Dermatology Specialists Of Northern Kentucky Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427007236 PECOS PAC ID: 2163485863 Enrollment ID: O20051005001084 |
News Archive
Patients with epilepsy often undergo evaluation by concurrent video and EEG monitoring (vEEG) for therapeutic planning, including possible epilepsy surgery. Seizures during monitoring increase the diagnostic yield and requires the withdrawal of anticonvulsant drugs (AEDs) to allow seizures to occur.
Inhibitex, Inc. today announced that the independent data safety monitoring board (DSMB) responsible for reviewing safety data from the Company's ongoing Phase II clinical trial of FV-100 met, as scheduled, after the Company had provided it with complete 30-day follow-up safety data on the third quartile (75%) of the patients that the Company plans to enroll in the trial. Based upon its review, the DSMB recommended that the trial continue to completion without modification.
Align Technology, Inc. today announced the launch of Invisalign® G3, the most significant collection of new features and innovations in the company's history. Invisalign G3 is engineered to deliver even better clinical results, with new aligner and software features that make it easier to use Invisalign with Class II and Class III patients, new SmartForce™ features designed for increased predictability of certain tooth movements, and simpler, more intuitive software to streamline treatment planning and review.
Targeting c-Met may be a promising personalized treatment method for approximately 45 percent of patients with hepatocellular carcinoma (HCC) who have c-Met-positive tumors, according to study results presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
First-trimester screening of pregnant women for asymptomatic bacteriuria - higher than normal bacteria levels without symptoms of a bladder infection - is recommended by the Canadian Task Force on Preventive Health Care in an updated guideline in CMAJ
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sarah Eilerman Weinel, MD 215 Thomas More Pkwy Ste A, Crestview Hills, KY 41017-3498 Ph: (859) 341-9588 | Dr Sarah Eilerman Weinel, MD 215 Thomas More Pkwy Ste A, Crestview Hills, KY 41017-3498 Ph: (859) 341-9588 |
News Archive
Patients with epilepsy often undergo evaluation by concurrent video and EEG monitoring (vEEG) for therapeutic planning, including possible epilepsy surgery. Seizures during monitoring increase the diagnostic yield and requires the withdrawal of anticonvulsant drugs (AEDs) to allow seizures to occur.
Inhibitex, Inc. today announced that the independent data safety monitoring board (DSMB) responsible for reviewing safety data from the Company's ongoing Phase II clinical trial of FV-100 met, as scheduled, after the Company had provided it with complete 30-day follow-up safety data on the third quartile (75%) of the patients that the Company plans to enroll in the trial. Based upon its review, the DSMB recommended that the trial continue to completion without modification.
Align Technology, Inc. today announced the launch of Invisalign® G3, the most significant collection of new features and innovations in the company's history. Invisalign G3 is engineered to deliver even better clinical results, with new aligner and software features that make it easier to use Invisalign with Class II and Class III patients, new SmartForce™ features designed for increased predictability of certain tooth movements, and simpler, more intuitive software to streamline treatment planning and review.
Targeting c-Met may be a promising personalized treatment method for approximately 45 percent of patients with hepatocellular carcinoma (HCC) who have c-Met-positive tumors, according to study results presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
First-trimester screening of pregnant women for asymptomatic bacteriuria - higher than normal bacteria levels without symptoms of a bladder infection - is recommended by the Canadian Task Force on Preventive Health Care in an updated guideline in CMAJ
› Verified 6 days ago
Stephanie Ann Snyder, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 215 Thomas More Pkwy Ste A, Crestview Hills, KY 41017 Phone: 859-341-9588 Fax: 859-341-0078 | |
William B. Hoppenjans, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 2701 Chancellor Dr, Crestview Hills, KY 41017 Phone: 859-341-1878 Fax: 859-341-0560 | |
Scott Andrew Neltner, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2701 Chancellor Dr, Crestview Hills, KY 41017 Phone: 859-341-1878 Fax: 859-341-0560 | |
Dr. Jason Robert Martin, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 651 Centre View Blvd, Crestview Hills, KY 41017 Phone: 859-371-3376 Fax: 859-331-1053 | |
Dr. Nicole Marie Warner, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 651 Centre View Blvd, Crestview Hills, KY 41017 Phone: 859-301-6647 Fax: 859-331-0809 |